Peter Sondermann

Synglyco, Inc. develops novel vaccines using synthetic carbohydrates. The firm's cutting edge technology enables the rapid, milligram to kilogram production of synthetic carbohydrates for use in drug discovery and industrial applications. Its proprietary platform generates significant quantities of chemically pure, complex carbohydrates through automated and manual chemical synthesis. The company was founded by Peter H. Seeberger, Carmichael S. Roberts Jr. Obadiah J. Plante and Louis Schofield on June 18, 2001 and is headquartered in New York, NY.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

Abbott GmbH & Co. KG develops and manufactures health care products. It is engaged in the discovery, development, manufacture, and marketing of pharmaceutical, diagnostic, nutritional, and hospital products. It offers pharmaceutical and diagnostic products ranging from prevention and diagnosis to treatment and cure. The company is headquartered in Ludwigshafen, Germany.

Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany.

Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA.

Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions.

Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany.

SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.

i2chem, Inc. develops integrated microchemical systems based on silicon micro reactors. The firm is a startup company commercializing micro reactors for chemical applications. The company was founded by Klavs Jensen & Peter H. Seeberger in 2005 and is headquartered in Sunnyvale, CA.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.

Chundsell Medicals AB develops and markets novel molecular diagnostics for the treatment of cancer. Its product measures the expression pattern of selected embryonic stem cell genes in prostate cancer core needle biopsies. The company was founded by Sunne Rosell and Chunde Li in 2007 and is headquartered in Solna, Sweden.

apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.

Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.

Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany.

coparion Komplementär GmbH (coparion) is an independent venture capital firm founded in 2015. The firm is headquartered in Cologne, Germany, with another German office located in Cologne.

neotiv GmbH provides neuroscience and dementia research and development services. The firm specializes in digital health, alzheimers and neuroscience. The company was founded by Chris Rehse, Julian Haupenthal, Emrah Duzel and David Berron and is headquartered in Magdeburg, Germany.

Kumovis GmbH provides additive manufacturing systems for medical products based on Fused Filament Fabrication. The company was founded by Miriam Haerst and Stefan Leonhardt and is headquartered in Taufkirchen, Germany.

Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom.

Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.